Hormonal
Tirzepatide (TZP) administration causes bone loss in obese diabetic mice by reducing gut microbiota biodiversity, specifically depleting Lachnospiraceae, which leads to lower levels of the metabolite evodiamine and subsequent increased osteoclastogenesis.
If you are taking Tirzepatide for diabetes or obesity, be aware that it may reduce bone density in your hips/femurs by altering gut bacteria. Discuss bone health monitoring with your doctor. The study suggests that maintaining gut health (specifically Lachnospiraceae bacteria) might protect bone, though probiotic supplementation is not yet a standard prescription.
We found that TZP intervention resulted in a significant decrease in bone mass accrual in vivo... The biodiversity of the gut microbiota in db/db mice was strikingly altered after TZP treatment. Lachnospiraceae, a key pro-osteogenic component of gut microbiota was significantly reduced. As a main metabolite of Lachnospiraceae, evodiamine played a role in suppressing osteoclastogenesis in vitro.
Why this rating
Evidence is derived from murine models (db/db mice) and in vitro assays; translational to humans is suggested but not directly proven in clinical trials within this text.
Source
Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites
Ning Chen et al. · Journal of Orthopaedic Translation · 2025
DOI 10.1016/j.jot.2025.09.002
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →